Activity Overview
This educational activity is an archive of the live presentation held on May 29, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward medical
oncologists, surgical oncologists, advanced practice professionals,
pathologists, oncology nurses, and other health care practitioners who manage
patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate emerging evidence from pivotal trials to determine their impact on evolving treatment paradigms in early-stage and metastatic triple-negative breast cancer (TNBC)
- Incorporate biomarker testing alongside patient-specific factors into personalized treatment plans for patients with TNBC
- Identify key differences in the safety profiles of PARP inhibitors, immunotherapies, and antibody-drug conjugates (ADCs) used for the treatment of TNBC
- Assess unique targets, structures, and mechanisms of novel therapies under investigation for the treatment of TNBC
Hope S. Rugo, MD, FASCO
Director, Women’s Cancers Program
Division Chief, Breast Medical
Oncology
Professor, Department of Medical
Oncology and Therapeutics Research
City of Hope Comprehensive
Cancer Center
Duarte, CA
Professor Emeritus, UCSF
San Francisco, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Consulting or advisory role for BioNTech, Bristol Myers Squibb, Helsinn, and Napo. Grant/Research Funding: Institutional research funding to prior institution, UCSF, from Ambryx, AstraZeneca, Daiichi Sankyo, Gilead Sciences, Inc., Lilly, Merck & Co., Novartis Pharmaceuticals, Pfizer, F. HoffmanLa Roche/Genentech, and Stemline Therapeutics; Institutional research funding to City of Hope from Bicycle Therapeutics, F. Hoffman- La Roche/Genentech, Merck, and Stemline Therapeutics
Neil M. Iyengar, MD
Associate Professor, Department of Hematology and Medical
Oncology
Co-Director, Breast Medical
Oncology,
Department of Hematology and
Medical Oncology
Director, Cancer Survivorship
Services
Emory University School of
Medicine
Atlanta, GA
Disclosures: Consultant/Advisor: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, MenariniStemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics; Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health; Editorial Position: npj Breast Cancer, Oncology®; Equity/Ownership: Complement Theory, Bettering Company; Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat’s Ribbon of Hope, National Cancer Institute/National Institutes of Health; Contracted Research: Novartis, SynDevRx
Heather McArthur, MD, MPH
Professor of Internal Medicine
Clinical Director, Breast Cancer
Program
Komen Distinguished Chair in
Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, TX
Disclosures: Consultant: Amgen, Arvinas, AstraZeneca, Bristol Myers Squibb, Calithera, Celgene, Daiichi Sankyo, Eli Lilly, Genentech/Roche, Immunomedics, Merck, OBI Pharma, Peregrine, Pfizer, Puma, Seattle Genetics, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, TapImmune; Grant/Research Support: Bristol Myers Squibb, BTG, MedImmune/AstraZeneca, Merck
Jason Aboudi Mouabbi, MD
Assistant Professor, Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD
Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agendia, Aptitude Health, AstraZeneca, BostonGene, Community Health Media, GE HealthCare, PreludeDX, Stemline; Grant/Research Funding: Bristol Myers Squibb, Summit Therapeutics
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
